References
- Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units — Causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study French study group on acute renal failure. Crit Care Med. 1996;24:192–8.
- Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al.. Continuous renal replacement therapy: A worldwide practice survey: The beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Intensive Care Med. 2007;33:1563–70.
- Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268–82.
- DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother. 2006;50:3529–34.
- Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc.; 1982.
- Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, et al.. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39:19–25.
- Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799–807.
- Naka T, Haase M, Bellomo R. ‘Super high-flux’ or ‘high cut-off’ hemofiltration and hemodialysis. Contrib Nephrol. 2010;166:181–9.
- Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64:151–8.